Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mel scale

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Mel scale. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-003030-17 Sponsor Protocol Number: 3475-002 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma
    Medical condition: Advanced melanoma (unresectable or metastatic)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) NO (Completed) SE (Completed) IT (Completed) NL (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004907-10 Sponsor Protocol Number: MK-3475-006 Start Date*: 2013-03-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)
    Full Title: A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Adv...
    Medical condition: Patients with advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) FR (Completed) DE (Completed) NL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001626-42 Sponsor Protocol Number: LPS14409 Start Date*: 2015-11-27
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabe...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) SK (Completed) DK (Completed) GR (Completed) SI (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002848-28 Sponsor Protocol Number: C LF23-0121 06 02 Start Date*: 2007-04-11
    Sponsor Name:FOURNIER Laboratories Ireland Ltd
    Full Title: An open label, multicenter trial assessing the acceptability of a new fixed dose combination of fenofibrate 80 mg bid and metformin 1000 mg bid in patients with type 2 diabetes (T2DM) and dyslipide...
    Medical condition: Patients with type 2 diabetes (T2DM) and dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004833-40 Sponsor Protocol Number: EFC10518 Start Date*: 2008-05-14
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monoth...
    Medical condition: Type 2 Diabetes patients insufficiently controlled with metformin monotherapy
    Disease: Version SOC Term Classification Code Term Level
    10.1 10067585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003126-16 Sponsor Protocol Number: CANA-1 Start Date*: 2016-10-27
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF THE ACUTE ADMINISTRATION OF THE SGLT-2 INHIBITOR CANAGLIFLOZIN ON CONTERREGULATORY RESPONS...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002847-96 Sponsor Protocol Number: DRI6012 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi aventis US Inc.
    Full Title: A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabe...
    Medical condition: The current study is designed to confirm the already observed clinically meaningful pharmacodynamic effect of AVE0010 on glycemic control, as measured by HbA1c, and to determine the clinically rele...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013264-39 Sponsor Protocol Number: VIAject-31J Start Date*: Information not available in EudraCT
    Sponsor Name:BIODEL inc.
    Full Title: A Single-Center, Double Blind, Randomized Crossover Study Evaluating Injection Site Toleration of VIAject® 7, VIAject® 25 and Insulin Lispro in Subjects with Type 1 or Type 2 Diabetes Mellitus
    Medical condition: Type 1 or Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000594-29 Sponsor Protocol Number: PEA001 Start Date*: 2007-04-25
    Sponsor Name:NHS Tayside
    Full Title: The use of glycaemic response to sulphonylureas as a tool to investigate Type 2 diabetes pathophysiology
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002910-38 Sponsor Protocol Number: U1111-1177-2744 Start Date*: 2016-10-10
    Sponsor Name:Hvidovre University Hospital
    Full Title: Basal-bolus insulin therapy with Insulin Degludec and insulin Aspart versus standard therapy for the inpatient management of type 2 diabetes: The IDA2 study
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003760-38 Sponsor Protocol Number: E7001-H001 Start Date*: 2005-10-14
    Sponsor Name:Sten Madsbad
    Full Title: Effect of three doses of nasal glp-1 versus placebo on postprandial hyperglycaemia in type 2 diabetes.
    Medical condition: postprandial hyperglycaemia in type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    10045242
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003716-36 Sponsor Protocol Number: D5670C00002 Start Date*: 2015-03-30
    Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca
    Full Title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects with a H...
    Medical condition: Type 2 Diabetes in Overweight and Obese Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003572-36 Sponsor Protocol Number: Start Date*: 2011-12-05
    Sponsor Name:Royal Devon & Exeter NHS Foundation Trust [...]
    1. Royal Devon & Exeter NHS Foundation Trust
    2. University of Exeter
    Full Title: The role of GLP-1 analogues in reducing reperfusion injury after acute stroke in patients with impaired swallowing.
    Medical condition: We plan to give a synthetic form of GLP-1 (Liraglutide) that is already available and licensed for use in patients with diabetes in the UK, to patients who have had an acute stroke, in order to det...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002079-24 Sponsor Protocol Number: NL61855.018.17 Start Date*: 2018-01-22
    Sponsor Name:Academic Medical Center
    Full Title: Targeting the secondary bile acid glycodeoxycholic acid as therapeutic strategy in type 2 diabetes mellitus.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001873-42 Sponsor Protocol Number: D1690R00009 Start Date*: 2015-10-27
    Sponsor Name:University of Liverpool
    Full Title: Pragmatic Randomised 104 Week Multicentre Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000398-21 Sponsor Protocol Number: NLY01-D1 Start Date*: 2019-08-26
    Sponsor Name:Neuraly, Inc.
    Full Title: A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, when Administered as a Single Dose in Subjects with Type 2 D...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002712-51 Sponsor Protocol Number: 2020 Start Date*: 2021-03-05
    Sponsor Name:Kirsi Pietiläinen
    Full Title: Semaglutide as an adjunct to dieting in the treatment of type 2 diabetes – effects on glucose metabolism, prevention of weight regain and peripheral tissue metabolic activation
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004533-13 Sponsor Protocol Number: EFC13470 Start Date*: 2015-07-17
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regi...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001140-61 Sponsor Protocol Number: GWDM1302 Start Date*: 2013-12-30
    Sponsor Name:GW Research Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes.
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000988-41 Sponsor Protocol Number: UoL000977 Start Date*: 2014-08-22
    Sponsor Name:University of Liverpool
    Full Title: A randomized, controlled multi-centre trial of 26 weeks of subcutaneous Liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with Type 2 Di...
    Medical condition: Obstructive Sleep Apnoea and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014722 10029983 Obstructive sleep apnoea syndrome LLT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 22:39:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA